Korea To Bolster Fast-Track System With Speedier Approvals In Mind
This article was originally published in PharmAsia News
Executive Summary
With a broad ambition to improve the global competitiveness of its biopharma industry, South Korea is steadily unveiling supportive regulatory measures. Among the planned steps this year are the strengthening and clarification of an existing fast-track review and approval system, although the government says a limited number of reviewers may hamper the improved handling of such evaluations.